Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 5/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PDE1A | P54750 | 1/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.35 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7037181 | 0.87 | LMNA (0.51) | FDPSADORA2APDE4APDE4BPDE4C | |
| SCHEMBL28447420 | 0.84 | ALDH1A1 (0.48) | FDPSADORA2ALMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL26999618 | 0.84 | ALDH1A1 (0.48) | FDPSADORA2ALMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL11745655 | 0.81 | — | — | |
| SCHEMBL13403286 | 0.80 | FDPS (0.43) | FDPSADORA2AADORA2BADORA1LMNA | |
| SCHEMBL16479467 | 0.80 | FDPS (0.43) | FDPSLMNAALDH1A1 | |
| SCHEMBL24168410 | 0.78 | ADORA2A (0.40) | ADORA2AADORA2BADORA1PDE4APDE4B | |
| SCHEMBL22546477 | 0.78 | ADORA2A (0.40) | ADORA2AADORA2BADORA1PDE4APDE4B | |
| Hydrochloric Acid SCHEMBL21774961 | 0.78 | FDPS (0.42) | FDPSADORA2BALDH1A1 | |
| SCHEMBL21554483 | 0.77 | ADORA2A (0.39) | ADORA2AADORA2BADORA1PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4273146-A1 | TRICYCLIC COMPOUND AND USE THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| EP-3567028-B1 | BIPHENYL COMPOUND AS CCR2/CCR5 RECEPTOR ANTAGONIST | MEDSHINE DISCOVERY INC (CN) | 2022-01-05 | — | — | EP | disclosed |
| US-11155523-B2 | Biphenyl compound as CCR2/CCR5 receptor antagonist | MEDSHINE DISCOVERY, INC. (CN) | 2021-10-26 | — | — | US | disclosed |
| EP-3747881-A1 | NITROGEN-CONTAINING BENZOHETEROCYCLE COMPOUND COMPRISING CARBOXYLIC ACID GROUP, PREPARATION METHOD AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2020-12-09 | — | — | EP | disclosed |
| US-20200223801-A1 | Biphenyl Compound As CCR2/CCR5 Receptor Antagonist | MEDSHINE DISCOVERY, INC. (CN) | 2020-07-16 | — | — | US | disclosed |
| EP-3567028-A1 | BIPHENYL COMPOUND AS CCR2/CCR5 RECEPTOR ANTAGONIST | Medshine Discovery Inc. (CN) | 2019-11-13 | — | — | EP | disclosed |
| WO-2019149089-A1 | NITROGEN-CONTAINING BENZOHETEROCYCLE COMPOUND COMPRISING CARBOXYLIC ACID GROUP, PREPARATION METHOD AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2019-08-08 | — | — | WO | disclosed |
| US-10278973-B2 | Hydroxyl purine compounds and use thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-05-07 | — | — | US | disclosed |
| US-20180140607-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-24 | — | — | US | disclosed |
| EP-3299371-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180140607-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | PNP, PDE7A, PDE2A | FDPS 351/4885ADORA2A 30/4885ADORA2B 89/4885 |
| US-10278973-B2 | Hydroxyl purine compounds and use thereof | PNP, PDE7A, PDE2A | FDPS 351/4885ADORA2A 30/4885ADORA2B 89/4885 |
| US-11155523-B2 | Biphenyl compound as CCR2/CCR5 receptor antagonist | CCR2, CCR5, CCRL2 | FDPS 3366/4885ADORA2A 410/4885ADORA2B 330/4885 |
| US-20200223801-A1 | Biphenyl Compound As CCR2/CCR5 Receptor Antagonist | CCR2, CCR5, CCRL2 | FDPS 3366/4885ADORA2A 410/4885ADORA2B 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.